Medtronic's stent-graft system gets CE marking:
This article was originally published in Clinica
Medtronic subsidiary, Medtronic AneuRx, has received European approval to affix CE marking to its endovascular stent-graft system. The system allows physicians to treat abdominal aortic aneurysms by getting at the site through a catheter placed in the femoral artery, offering a less-invasive alternative to open abdominal surgery.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.